Comparing Efficacy, Safety, and Practicality of BCMA-Directed Therapies in Early Relapsed Multiple Myeloma
Abstract
Although 3 combination-based B-cell maturation antigen–directed therapies demonstrate remarkable efficacy in early relapsed multiple myeloma, teclistamab plus daratumumab has emerged as the most practical option for most patients. However, the high infection rate demands urgent investigation of time-limited treatment strategies.
Fields of Study & Subjects
Multiple Myeloma Research and Treatments
Monoclonal and Polyclonal Antibodies Research
CAR-T cell therapy research
Publication details
- Journal / source
- Default Digital Object Group
- Publication date
- 4 March 2026
- Language
- EN
- Document type
- Dataset